1. Q4 same store sales decreased only 0.5% from last year. 2. Q4 adjusted EBITDA improved to $14.6 million from $5.3 million. 3. Net debt reduced by $27.3 million; liquidity now $131.1 million. 4. Sales growth anticipated in fishing category; overall sales outlook mixed. 5. Management optimistic about achieving same store sales growth in 2025.

1. ConnectM received a $1.60/share acquisition offer from major investors. 2. The offer values the company at approximately $46.5 million. 3. Investors are increasing their stakes, indicating strong commitment. 4. The transaction requires due diligence and regulatory approvals. 5. ConnectM aims to enhance its role in the modern energy economy.

1. LPRO reported a $144.4 million net loss in Q4 2024. 2. Board changes include Jessica Buss as CEO and Michelle Glasl as COO. 3. Certified loans fell to 26,065 in Q4 compared to 26,263 a year prior. 4. Total revenue for 2024 dropped to $24 million from $117.5 million in 2023. 5. Profit share revenue forecast was adjusted downward by $81.3 million.

1. Nutex Health's revenue soared 93.8% to $479.9 million in 2024. 2. Net income was $52.2 million, reversing a loss from 2023. 3. Arbitration contributed significantly, adding $169.7 million to revenue. 4. Adjusted EBITDA increased over 1,000% year-on-year to $123.7 million. 5. Company sees continued operational improvements and revenue growth.

1. MySize's revenue increased 18% to $8.26 million year-over-year. 2. Net loss decreased by 37%, showcasing improved financial health. 3. Cash reserves more than doubled, indicating stronger liquidity. 4. Over 100 brands adopted MySize's AI sizing solutions, enhancing market reach. 5. Significant tech integrations support e-commerce expansions and client retention.

1. AEHL announces a 1-for-40 reverse stock split effective April 4, 2025. 2. The split is to meet NASDAQ's minimum bid price requirement of $1.00. 3. If AEHL fails to maintain the price, it risks delisting from NASDAQ. 4. The number of shares will decrease from 41 million to approximately 1 million. 5. Shareholders' rights and options will be adjusted post-split.

1. RxSight expects Q1 2025 revenue of $37.9 million, 28% year-over-year growth. 2. Revenue guidance for 2025 revised down to $160 million - $175 million. 3. Operating costs are also revised upward, expect $150 million - $160 million. 4. Installed base of Light Delivery Devices has increased to 1,044 units, 43% up. 5. CEO acknowledges broader economic headwinds affecting premium IOL market.

1. GORV faced challenges in revenue, reporting $159.9 million in Q4 2024. 2. Net loss is $96.1 million for Q4 2024, improved from $108 million in Q4 2023. 3. The company plans to divest three store locations to strengthen its balance sheet. 4. Annual revenue fell to $871.6 million, down from $1,082.7 million in 2023. 5. Adjustments included significant impairment charges affecting liquidity and operations.

1. Revenue increased 23.9% to $379.8 million in FY 2024. 2. Q4 2024 gross margin rose to 36.6%, up from 22.0% in Q4 2023. 3. Company backlog grew to $401.3 million, indicating strong future demand. 4. Huzhou Phase 3.2 expansion expected to meet rising customer demand by Q4 2025. 5. 2025 revenue guidance targets $450 million to $475 million, reflecting sustained growth.

1. Glucotrack advanced to clinical stage with CBGM technology. 2. Secured $16.3 million in funding for development milestones. 3. Leadership team strengthened with key appointments in 2024. 4. CBGM expected to receive FDA IDE approval by Q4 2025. 5. Promising results from initial human clinical study reported.